SARS-CoV-2 Testing Before International Airline Travel, December 2020 to May 2021
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved..
Although there have been several case reports and simulation models of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission associated with air travel, there are limited data to guide testing strategy to minimize the risk of SARS-CoV-2 exposure and transmission onboard commercial aircraft. Among 9853 passengers with a negative SARS-CoV-2 polymerase chain reaction test performed within 72 hours of departure from December 2020 through May 2021, five (0.05%) passengers with active SARS-CoV-2 infection were identified with rapid antigen tests and confirmed with rapid molecular test performed before and after an international flight from the United States to Italy. This translates to a case detection rate of 1 per 1970 travelers during a time of high prevalence of active infection in the United States. A negative molecular test for SARS-CoV-2 within 72 hours of international airline departure results in a low probability of active infection identified on antigen testing during commercial airline flight.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:96 |
|---|---|
| Enthalten in: |
Mayo Clinic proceedings - 96(2021), 11 vom: 09. Nov., Seite 2856-2860 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tande, Aaron J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 17.11.2021 Date Revised 17.11.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.mayocp.2021.08.019 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332747085 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332747085 | ||
| 003 | DE-627 | ||
| 005 | 20231225220219.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.mayocp.2021.08.019 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1109.xml |
| 035 | |a (DE-627)NLM332747085 | ||
| 035 | |a (NLM)34736612 | ||
| 035 | |a (PII)S0025-6196(21)00644-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tande, Aaron J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2 Testing Before International Airline Travel, December 2020 to May 2021 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.11.2021 | ||
| 500 | |a Date Revised 17.11.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Although there have been several case reports and simulation models of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission associated with air travel, there are limited data to guide testing strategy to minimize the risk of SARS-CoV-2 exposure and transmission onboard commercial aircraft. Among 9853 passengers with a negative SARS-CoV-2 polymerase chain reaction test performed within 72 hours of departure from December 2020 through May 2021, five (0.05%) passengers with active SARS-CoV-2 infection were identified with rapid antigen tests and confirmed with rapid molecular test performed before and after an international flight from the United States to Italy. This translates to a case detection rate of 1 per 1970 travelers during a time of high prevalence of active infection in the United States. A negative molecular test for SARS-CoV-2 within 72 hours of international airline departure results in a low probability of active infection identified on antigen testing during commercial airline flight | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Binnicker, Matthew J |e verfasserin |4 aut | |
| 700 | 1 | |a Ting, Henry H |e verfasserin |4 aut | |
| 700 | 1 | |a Del Rio, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Jalil, Lindsey |e verfasserin |4 aut | |
| 700 | 1 | |a Brawner, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Carter, Peter W |e verfasserin |4 aut | |
| 700 | 1 | |a Toomey, Kathleen |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Nilay D |e verfasserin |4 aut | |
| 700 | 1 | |a Berbari, Elie F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Mayo Clinic proceedings |d 1964 |g 96(2021), 11 vom: 09. Nov., Seite 2856-2860 |w (DE-627)NLM000074527 |x 1942-5546 |7 nnns |
| 773 | 1 | 8 | |g volume:96 |g year:2021 |g number:11 |g day:09 |g month:11 |g pages:2856-2860 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.mayocp.2021.08.019 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 96 |j 2021 |e 11 |b 09 |c 11 |h 2856-2860 | ||